Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isis 420915 in Wild-Type Transthyretin Amyloid Cardiomyopathy
NCT02627820Phase 2Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2018
01
Overview
A Phase 2 trial of inotersen in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), sponsored by Brigham and Women's Hospital. Planned start Jan 2016; status: withdrawn.
02
Drugs
inotersen
03
Conditions
wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)
Beyond the preview
Go deeper on NCT02627820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627820.